β2-Microglobulin, cystatin C, and creatinine and risk of symptomatic peripheral artery disease

Journal of the American Heart Association

Volumn 3, Issue 4, 2014, Pages

  Joosten, Michel M ^a,b,c,d   Pai, Jennifer K ^b,e   Bertoia, Monica L ^a,b   Gansevoort, Ron T ^d   Bakker, Stephan J L ^c,d   Cooke, John P ^f   Rimm, Eric B ^b,e   Mukamal, Kenneth J ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e HARVARD MEDICAL SCHOOL   (United States)

^f HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Creatinine; Cystatin C; Kidney; Peripheral artery disease; 2 microglobulin

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE; CYSTATIN C; BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NESTED CASE CONTROL STUDY; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; BLOOD; INCIDENCE; INTERMITTENT CLAUDICATION; LONGITUDINAL STUDY; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PROGNOSIS; STATISTICAL MODEL;

AGED; BETA 2-MICROGLOBULIN; BIOMARKERS; CASE-CONTROL STUDIES; CREATININE; CYSTATIN C; FEMALE; HUMANS; INCIDENCE; INTERMITTENT CLAUDICATION; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84923563028     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.000803     Document Type: Article

References (48)

1. Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation. 2011;124:17-23.
2. McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, Pearce WH, Schneider JR, Ferrucci L, Celic L, Taylor LM, Vonesh E, Martin GJ, Clark E. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA. 2004;292:453-461.
3. Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G, Wautrecht JC, Kornitzer M, Newman AB, Cushman M, Sutton-Tyrrell K, Lee AJ, Price JF, d'Agostino RB, Murabito JM, Norman PE, Jamrozik K, Curb JD, Masaki KH, Rodriguez BL, Dekker JM, Bouter LM, Heine RJ, Nijpels G, Stehouwer CD, Ferrucci L, McDermott MM, Stoffers HE, Hooi JD, Knottnerus JA, Ogren M, Hedblad B, Witteman JC, Breteler MM, Hunink MG, Hofman A, Criqui MH, Langer RD, Fronek A, Hiatt WR, Hamman R, Resnick HE, Guralnik J. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197-208.
4. Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality implications. Circulation. 2006;114:688-699.
5. Joosten MM, Pai JK, Bertoia ML, Rimm EB, Spiegelman D, Mittleman MA, Mukamal KJ. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA. 2012;308:1660-1667.
6. Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, Kuller LH, Newman AB. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 2003;41:1364-1372.
7. O'Hare AM, Vittinghoff E, Hsia J, Shlipak MG. Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/Progestin Replacement Study (HERS). J Am Soc Nephrol. 2004; 15:1046-1051.
8. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Intersociety consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45:S5-S67.
9. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;suppl 3:1-150.
10. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17-28.
11. Astor BC, Levey AS, Stevens LA, Van Lente F, Selvin E, Coresh J. Method of glomerular filtration rate estimation affects prediction of mortality risk. J Am Soc Nephrol. 2009;20:2214-2222.
12. Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, Froissart M, Kusek JW, Zhang YL, Coresh J, Levey AS. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75:652-660.
13. Jovanovic D, Krstivojevic P, Obradovic I, Durdevic V, Dukanovic L. Serum cystatin C and beta2-microglobulin as markers of glomerular filtration rate. Ren Fail. 2003;25:123-133.
14. Juraschek SP, Coresh J, Inker LA, Levey AS, Kottgen A, Foster MC, Astor BC, Eckfeldt JH, Selvin E. Comparison of serum concentrations of beta-trace protein, beta2-microglobulin, cystatin C, and creatinine in the US population. Clin J Am Soc Nephrol. 2013;8:584-592.
15. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem. 2005;38:1-8.
16. Vincent C, Chanard J, Caudwell V, Lavaud S, Wong T, Revillard JP. Kinetics of 125I-beta 2-microglobulin turnover in dialyzed patients. Kidney Int. 1992; 42:1434-1443.
17. Randers E, Kristensen JH, Erlandsen EJ, Danielsen H. Serum cystatin C as a marker of the renal function. Scand J Clin Lab Invest. 1998;58:585-592.
18. Bianchi C, Donadio C, Tramonti G, Consani C, Lorusso P, Rossi G. Reappraisal of serum beta2-microglobulin as marker of GFR. Ren Fail. 2001;23:419-429.
19. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049-2060.
20. Shlipak MG, Matsushita K, Arnlov J, Inker LA, Katz R, Polkinghorne KR, Rothenbacher D, Sarnak MJ, Astor BC, Coresh J, Levey AS, Gansevoort RT. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369:932-943.
21. Shinkai S, Chaves PH, Fujiwara Y, Watanabe S, Shibata H, Yoshida H, Suzuki T. Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein. Arch Intern Med. 2008;168:200-206.
22. Astor BC, Shafi T, Hoogeveen RC, Matsushita K, Ballantyne CM, Inker LA, Coresh J. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis. 2012;59:653-662.
23. Albert MA, Rifai N, Ridker PM. Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. Vasc Med. 2001;6:145-149.
24. O'Hare AM, Newman AB, Katz R, Fried LF, Stehman-Breen CO, Seliger SL, Siscovick DS, Shlipak MG. Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. Arch Intern Med. 2005;165:2666-2670.
25. Wilson AM, Kimura E, Harada RK, Nair N, Narasimhan B, Meng XY, Zhang F, Beck KR, Olin JW, Fung ET, Cooke JP. Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation. 2007;116:1396-1403.
26. Fung ET, Wilson AM, Zhang F, Harris N, Edwards KA, Olin JW, Cooke JP. A biomarker panel for peripheral arterial disease. Vasc Med. 2008;13:217-224.
27. Prentice RL, Breslow NE. Retrospective studies and failure time models. Biometrika. 1978;65:153-158.
28. Spithoven EM, Bakker SJ, Kootstra-Ros JE, de Jong PE, Gansevoort RT. Stability of creatinine and cystatin C in whole blood. Clin Biochem. 2013;46:1611-1614.
29. Joosten MM, Joshipura KJ, Pai JK, Bertoia ML, Rimm EB, Mittleman MA, Mukamal KJ. Total adiponectin and risk of symptomatic lower extremity peripheral artery disease in men. Arterioscler Thromb Vasc Biol. 2013;33:1092-1097.
30. Ascherio A, Rimm E, Giovannucci E, Colditz G, Rosner B, Willett W, Sacks F, Stampfer M. A prospective study of nutritional factors and hypertension among US men. Circulation. 1992;86:1475-1484.
31. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 2007;69:1688-1695.
32. Joosten MM, Chiuve SE, Mukamal KJ, Hu FB, Hendriks HF, Rimm EB. Changes in alcohol consumption and subsequent risk of type 2 diabetes in men. Diabetes. 2011;60:74-79.
33. Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC. Validity of self-reported waist and hip circumferences in men and women. Epidemiology. 1990;1:466-473.
34. Chasan-Taber S, Rimm EB, Stampfer MJ, Spiegelman D, Colditz GA, Giovannucci E, Ascherio A, Willett WC. Reproducibility and validity of a selfadministered physical activity questionnaire for male health professionals. Epidemiology. 1996;7:81-86.
35. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
36. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012; 367:20-29.
37. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8:551-561.
38. Prentice RL, Paczesny S, Aragaki A, Amon LM, Chen L, Pitteri SJ, McIntosh M, Wang P, Buson Busald T, Hsia J, Jackson RD, Rossouw JE, Manson JE, Johnson K, Eaton C, Hanash SM. Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling. Genome Med. 2010;2:48.
39. Woitas RP, Stoffel-Wagner B, Poege U, Schiedermaier P, Spengler U, Sauerbruch T. Low-molecular weight proteins as markers for glomerular filtration rate. Clin Chem. 2001;47:2179-2180.
40. Gorevic PD, Casey TT, Stone WJ, DiRaimondo CR, Prelli FC, Frangione B. Beta-2 microglobulin is an amyloidogenic protein in man. J Clin Invest. 1985; 76:2425-2429.
41. Takayama F, Miyazaki S, Morita T, Hirasawa Y, Niwa T. Dialysis-related amyloidosis of the heart in long-term hemodialysis patients. Kidney Int Suppl. 2001;78:S172-S176.
42. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.
43. Delgado J, Pratt G, Phillips N, Briones J, Fegan C, Nomdedeu J, Pepper C, Aventin A, Ayats R, Brunet S, Martino R, Valcarcel D, Milligan D, Sierra J. Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. Br J Haematol. 2009;145:801-805.
44. Alexanian R, Barlogie B, Fritsche H. Beta 2 microglobulin in multiple myeloma. Am J Hematol. 1985;20:345-351.
45. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WRC, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM, White CJ, White J, White RA. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation. 2006;113:e463-e654.
46. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, Golzarian J, Gornik HL, Halperin JL, Jaff MR, Moneta GL, Olin JW, Stanley JC, White CJ, White JV, Zierler RE. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline). Circulation. 2011;124:2020-2045. Published online before print September 29, 2011, doi: 10.1161/CIR.0b013e31822e80c3.
47. Bertoia ML, Pai JK, Lee JH, Taleb A, Joosten MM, Mittleman MA, Yang X, Witztum JL, Rimm EB, Tsimikas S, Mukamal KJ. Oxidation-specific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol. 2013; 61:2169-2179.
48. Nitsch D, Grams M, Sang Y, Black C, Cirillo M, Djurdjev O, Iseki K, Jassal SK, Kimm H, Kronenberg F, Oien CM, Levey AS, Levin A, Woodward M, Hemmelgarn BR. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ. 2013;346:f324.